AcelRX Pharmaceuticals Stock Price - ACRX

0.02 (1.57%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
AcelRX Pharmaceuticals Inc ACRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.05 -3.79% 1.27 1.12 1.32 1.30 1.32 00:00:00
Bid Price Ask Price Spread Spread % News
0.61 1.80 1.19 66.11% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,102 1,068,393 $ 1.25 $ 1,332,006 1,295,472 0.7014 - 4.05
Last Trade Time Type Quantity Stock Price Currency
19:53:50 1 $ 1.29 USD

AcelRX Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 102.12M 80.41M $ -47.15M -0.67 - 78.03M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

AcelRX Pharmaceuticals News

Loading Messages....

Latest ACRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ACRX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.91411.460.70141.121,992,6130.355938.93%
1 Month1.201.500.70141.141,413,4980.075.83%
3 Months2.022.130.70141.431,002,125-0.75-37.13%
6 Months2.262.500.70141.74949,001-0.99-43.81%
1 Year3.174.050.70142.371,080,945-1.90-59.94%
3 Years3.005.750.70143.011,329,472-1.73-57.67%
5 Years3.855.880.70143.12951,563-2.58-67.01%

AcelRX Pharmaceuticals Description

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.